According to FutureWise analysis the Insomnia Treatment Market in 2025 is US$ 3.68 billion, and is expected to reach US$ 5.57 billion by 2033 at a CAGR of 5.32%. The insomnia treatment market is growing due to the rise in sleep disorders linked to modern stress, an aging population, and greater awareness of mental health. Key advancements include pharmacological therapies like orexin receptor antagonists and melatonin receptor agonists, along with digital therapeutics and CBT-based interventions.
The growing cases of insomnia worldwide due to rising stress levels has led to the growth of this market. With rising geriatric population coupled with awareness about numerous therapies and treatments in the market, support and propel the market’s growth. With advancements in technology and invention of better, efficient, new therapies providing quick, positive results, the public is more open to accepting such cures. Thus the increase in the launch of novel products such as MerckCo.’s Belsomra is projected to fuel high demand. Moreover, the availability of multiple generics is expected to boost the insomnia therapeutics market over the forecast period. Lemborexant, a novel Orexin Receptor Antagonist (ORA) by Eisai is expected to be launched in the near future, which may promote growth.
With new products and technology employed the market is estimated to soar unboundedly. Additionally, quite a few medical devices have been approved in the recent years such as EBB Insomnia Therapy, Fisher Wallace Stimulator, and Alpha-Stim AID, which are expected to have higher penetration due to favourable reimbursement policies and adoption of the device-drug combination therapies for treating insomnia.
Dual Orexin Receptor Antagonists (DORAs): Medications such as daridorexant are gaining attention for their effectiveness in improving sleep without the dependency risks associated with traditional hypnotics. However, its uptake has been variable due to issues related to cost and awareness.
Sleep Restriction Techniques: New strategies, such as minimizing time spent in bed, are being investigated to reduce anxiety and depression, potentially providing a low-cost, scalable treatment solution.
AI-Driven Interventions: Tools like NeuroPal, a large language model assistant, provide personalized sleep chronotherapy and cognitive-behavioral interventions, demonstrating high adherence rates and improvements in sleep quality.